Altrenogest - CAS 850-52-2
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
CAS Number:
Altrenogest is a progestogen structurally related to veterinary steroid trenbolone.
Molecular Weight:
Molecular Formula:
Progesterone Receptor
Chemical Structure
CAS 850-52-2 Altrenogest

Related Progesterone Receptor Products

CAS 67392-87-4 Drospirenone

(CAS: 67392-87-4)

Drospirenone is a synthetic hormone used in birth control pills and postmenopausal hormone replacement therapy pills.

CAS 297-76-7 Ethynodiol diacetate

Ethynodiol diacetate
(CAS: 297-76-7)

Ethynodiol diacetate is one of the first synthetic progestogens used in contraceptive pills.Relative to other 19-nortestosterone derivatives, it has relatively ...

(CAS: 209331-43-1)

CP-8668 is an orally active nonsteroidal progesterone receptor modulator with no significant affinity for human glucocorticoid receptor or human estrogen recept...

AG 205
(CAS: 442656-02-2)

AG-205 is a novel Pgrmc1 (progesterone receptor membrane component 1) inhibitor, alters the spectroscopic properties of the Pgrmc1-heme complex.

(CAS: 1262108-14-4)

Vilaprisan is a selective oral progesterone receptor antagonist under the development of Bayer HealthCare Pharmaceuticals. BAY 1002670 showed a marked dose-depe...

(CAS: 240805-96-3)

JNJ-1250132, a new steroidal progestin antagonist, inhibits binding of the receptor to DNA in vitro. JNJ-1250132 induces a receptor conformation more similar to...

CAS 304853-42-7 Tanaproget

(CAS: 304853-42-7)

Tanaproget is a novel nonsteroidal progesterone receptor agonist that is first in its class and has high affinity and selectivity for the progesterone receptor....

CAS 152-62-5 Dydrogesterone

(CAS: 152-62-5)

Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.

CAS 126784-99-4 Ulipristal Acetate

Ulipristal Acetate
(CAS: 126784-99-4)

Ulipristal Acetate is an orally bioactive and selective progesterone receptor modulator (SPRM) used for emergency contraception and uterine fibroid. It binds to...

CAS 797-63-7 Levonorgestrel

(CAS: 797-63-7)

Levonorgestrel is a synthetic progestogen used as an active ingredient in some hormonal contraceptives.

CAS 520-85-4 Medroxy Progesterone

Medroxy Progesterone
(CAS: 520-85-4)

Medroxy Progesterone is an orally active progestogen used in hormone replacement therepy (HRT).

CAS 84371-65-3 Mifepristone

(CAS: 84371-65-3)

Mifepristone is a progesterone receptor antagonist(IC50= 0.2 nM) and a glucocorticoid receptor antagonist(IC50= 2.6 nM). It is used as an abortifacient in the f...

CAS 71-58-9 Medroxyprogesterone acetate

Medroxyprogesterone acetate
(CAS: 71-58-9)

Medroxyprogesterone acetate is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

CAS 595-33-5 Megestrol Acetate

Megestrol Acetate
(CAS: 595-33-5)

Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HepG2.

CAS 198414-30-1 Telapristone

(CAS: 198414-30-1)

Telapristone, the active metabolite of telapristone acetate (also known as CDB-4124), is a selective progesterone antagonist developed for the long-term treatme...

CAS 850-52-2 Altrenogest

(CAS: 850-52-2)

Altrenogest is a progestogen structurally related to veterinary steroid trenbolone.

CAS 54024-22-5 Desogestrel

(CAS: 54024-22-5)

Desogestrel is a progestogen with low androgenic potency used in hormonal contraceptives..

CAS 68-22-4 Norethindrone

(CAS: 68-22-4)

Norethindrone, a synthetic progestin, is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).

CAS 302-22-7 Chlormadinone acetate

Chlormadinone acetate
(CAS: 302-22-7)

Chlormadinone acetate, with antiandrogen and antiestrogenic activities it is a steroidal progestin used in combinations as an oral contraceptive.

Telapristone acetate
(CAS: 198414-31-2)

Telapristone acetate, also known as CDB-4124, acts as an investigational selective progesterone receptor modulator (SPRM) tested for treatment of progesterone s...

Reference Reading

1.Supplementary corpora lutea monitoring allows progestin treatment interruption on day 70 of pregnancy in non-cyclic recipient mares.
Silva ES1, Frade SC2, Ignácio FS3, Pantoja JC4, Puoli Filho JN5, Meira C3. Anim Reprod Sci. 2014 Jan 30;144(3-4):122-8. doi: 10.1016/j.anireprosci.2013.12.004. Epub 2013 Dec 14.
The present study evaluated the effect of altrenogest treatment during 70 or 120 days of gestation on pregnancy maintenance in non-cyclic recipient mares and correlated the hormonal interruption findings with number, supplementary corpora lutea (SCL) formation period, and plasma progesterone (P4). Twenty five mares were used as recipients during anestrus, transitional or ovulatory phase and were assigned into groups according to altrenogest treatment period (70ALT, 120ALT or Control groups) or reproductive status at beginning of treatment (Anestrus, Transition or Cyclic/Control groups). Mares were evaluated by ultrasonography and quantification of plasma progesterone to monitor pregnancy status, SCL formation and P4 profile. After hormonal withdrawal, abortion was only observed on group 70ALT. The days of first SCL formation were similar (p=0.32) in the 70ALT and 120ALT groups and greater (p<0.01) than the Control group. In addition, the first SCL formation period occurred later during gestation in the anestrus group than in the transitional or cyclic mares.
2.Follicle size and reproductive hormone profiles during a post-weaning altrenogest treatment in primiparous sows.
van Leeuwen JJ1, Martens MR2, Jourquin J3, Driancourt MA4, Wagner A5, Kemp B1, Soede NM1. Reprod Fertil Dev. 2015 Jan;27(2):304-12. doi: 10.1071/RD13149.
This study investigated the endocrine background of follicle size changes during post-weaning altrenogest treatment. altrenogest-treated sows received a 20-mg dosage daily at 8.00 a.m. from Day -1 to Day 14 after weaning. On Day -1, only 3/13 altrenogest-treated sows showed LH pulses compared with 8/8 control sows (P=0.001). On Day 0, control sows showed a typical high frequency-low amplitude LH pattern, indicative for recruitment of oestrogenic follicles. In altrenogest-treated animals on Day 0, half of the sows showed high frequency-high amplitude pulses from 4-5h after weaning. In altrenogest-treated sows, average follicle size increased from 3.1±0.5 mm on Day 0 to 4.4±0.6mm on Day 5, then decreased to 3.7±0.5 mm on Day 7 and stabilised thereafter. FSH and oestradiol (E2) concentrations showed a distinct diurnal pattern; high at 7.00 a.m. and low at 3.00 p.m. E2 concentrations (7.00 a.m.) showed a 2.5-fold increase from Day -1 to Day 2, and subsequently a 2-fold decline to reach a plateau at Day 8.
3.Effect of a GnRH analogue (Maprelin) on the reproductive performance of gilts and sows.
de Jong E1, Kauffold J, Engl S, Jourquin J, Maes D. Theriogenology. 2013 Nov;80(8):870-7. doi: 10.1016/j.theriogenology.2013.07.012. Epub 2013 Aug 27.
The ability of peforelin (l-GnRH-III) to stimulate follicular growth, FSH release, and estrus in gilts after altrenogest treatment and in sows after weaning was investigated. In three farrow-to-wean herds, with at least 600 sows and average production performance, 216 gilts, 335 primiparous, and 1299 pluriparous sows were randomly allocated to three treatments: peforelin (M group: Maprelin), eCG (F group: Folligon), and physiological saline solution (C group). Animals were treated 48 hours after their last altrenogest treatment (gilts) or 24 hours after weaning (sows). The weaning-to-estrus interval, estrus duration, estrus rate (ER), pregnancy rate, and total born (TB), live born, and stillborn (SB) numbers were recorded and compared between treatments for the different parity groups (gilts and primiparous and pluriparous sows). Follicle sizes were measured in representative animals from each group on the occasion of their last altrenogest treatment or at weaning, and also on the occasions of their first (FS1) and second (FS2) attempted inseminations.
4.The use of altrenogest to avoid hyperestrogenism after eCG-hCG ovulation induction in southern tigrina (Leopardus guttulus).
Micheletti T1, Brown JL2, Walker SL3, Cubas ZS4, Furtado PV5, Putman SB2, de Moraes W4, de Oliveira MJ4, de Oliveira CA5, Moreira N6. Theriogenology. 2015 Sep 1;84(4):575-82. doi: 10.1016/j.theriogenology.2015.04.015. Epub 2015 Apr 28.
The goal of this study was to optimize an ovulation induction protocol for use with artificial insemination in the southern tigrina (Leopardus guttulus). The specific aims were to report the efficacy of using altrenogest, an oral progestin (Regumate, MSD Animal Health, Merck Animal Health), to suppress ovarian activity and prevent follicular hyperstimulation and hyperestrogenism after the administration of exogenous eCG and hCG. To monitor ovarian responses, fecal estrogen and progestogen metabolites were quantified by enzyme immunoassay in females before and after intramuscular administration of 200-IU eCG and 150-IU hCG in two trials, 4 months apart. During the first trial, there was no use of altrenogest, only the eCG-hCG ovulation induction protocol. In the second trial, the ovulation induction protocol was preceded by the administration of oral altrenogest for 14 days (minimum of 0.192 mg per kg per day). Altrenogest administration resulted in a suppression of follicular activity in three out of six females before eCG-hCG administration on the basis of lower mean estrogen concentrations (P < 0.